Mizuho lowered the firm’s price target on Surgery Partners (SGRY) to $22 from $28 and keeps an Outperform rating on the shares. The firm reduced its estimates for Surgery Partners to account for the lower-than-expected performance, lower earnings visibility due to payer mix pressure, and to remove M&A from its forecasts. Though the payer mix volume pressures reduce earnings visibility, the firm believes its estimates reflect that risk.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGRY:
- Surgery Partners price target lowered to $29 from $34 at UBS
- Surgery Partners Appoints New COO and President
- Strategic Growth and Portfolio Optimization Drive Buy Rating for Surgery Partners
- Surgery Partners price target lowered to $31 from $35 at RBC Capital
- Surgery Partners price target lowered to $30 from $35 at Benchmark